HK1231561A1 - 癌症治療 - Google Patents

癌症治療

Info

Publication number
HK1231561A1
HK1231561A1 HK17105244.4A HK17105244A HK1231561A1 HK 1231561 A1 HK1231561 A1 HK 1231561A1 HK 17105244 A HK17105244 A HK 17105244A HK 1231561 A1 HK1231561 A1 HK 1231561A1
Authority
HK
Hong Kong
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
HK17105244.4A
Other languages
English (en)
Inventor
．馬丁尼
．塔拉齊
．威廉斯
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HK1231561A1 publication Critical patent/HK1231561A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK17105244.4A 2014-04-24 2017-05-24 癌症治療 HK1231561A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983951P 2014-04-24 2014-04-24
PCT/IB2015/052796 WO2015162532A1 (en) 2014-04-24 2015-04-16 Cancer treatment

Publications (1)

Publication Number Publication Date
HK1231561A1 true HK1231561A1 (zh) 2017-12-22

Family

ID=53398149

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105244.4A HK1231561A1 (zh) 2014-04-24 2017-05-24 癌症治療

Country Status (24)

Country Link
US (2) US20170184602A1 (zh)
EP (1) EP3134119B1 (zh)
JP (1) JP6603474B2 (zh)
KR (1) KR101943177B1 (zh)
CN (1) CN106233143B (zh)
AR (1) AR100169A1 (zh)
AU (3) AU2015249513A1 (zh)
BR (1) BR112016024143A2 (zh)
CA (1) CA2946362C (zh)
CY (1) CY1120731T1 (zh)
DK (1) DK3134119T3 (zh)
ES (1) ES2691213T3 (zh)
HK (1) HK1231561A1 (zh)
HU (1) HUE040167T2 (zh)
IL (1) IL247859B (zh)
MX (1) MX2016013910A (zh)
PL (1) PL3134119T3 (zh)
PT (1) PT3134119T (zh)
RU (1) RU2651469C1 (zh)
SG (1) SG11201607918TA (zh)
SI (1) SI3134119T1 (zh)
TR (1) TR201815682T4 (zh)
TW (1) TWI568439B (zh)
WO (1) WO2015162532A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6945199B2 (ja) 2017-05-19 2021-10-06 国立大学法人山口大学 アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法
EP3820522A4 (en) 2018-07-12 2022-05-18 Corvus Pharmaceuticals, Inc. METHODS FOR DETECTING AND TREATING CANCERS HAVING ACTIVATION OF THE ADENOSINE PATHWAY
CA3106038A1 (en) * 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
US10936768B2 (en) * 2018-10-15 2021-03-02 Aible, Inc. Interface for visualizing and improving model performance
US10586164B1 (en) 2018-10-15 2020-03-10 AIble Inc. Interface for visualizing and improving model performance
WO2021076852A1 (en) * 2019-10-17 2021-04-22 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
WO2023217889A1 (en) * 2022-05-11 2023-11-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of bmmf1 rep protein as diagnostic marker for lung cancer
WO2023217886A1 (en) * 2022-05-11 2023-11-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of bmmf1 rep protein as diagnostic marker for pancreatic cancer and diabetes mellitus type 2
WO2024026407A1 (en) * 2022-07-28 2024-02-01 The Board Of Regents Of The University Of Oklahoma Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095634A1 (en) 2003-10-16 2005-05-05 Genomic Health Inc. qRT-PCR assay system for gene expression profiling
WO2005100606A2 (en) * 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
JP2009512860A (ja) * 2005-10-21 2009-03-26 バイエル ヘルスケア エルエルシー がんの予測及び予後の検査方法、並びにがん治療のモニタリング
US20070128636A1 (en) * 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
AU2007277144B2 (en) * 2006-07-28 2012-01-19 Novartis Ag Use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma
EP2088863A2 (en) * 2006-11-22 2009-08-19 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
CN102473202B (zh) * 2009-07-08 2015-11-25 环球创新网络公司 用于预测药物在患者中的疗效的方法
CA2772670A1 (en) * 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
JP2014503500A (ja) * 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
KR102009007B1 (ko) * 2011-10-04 2019-08-08 인비비스 파마슈티컬스 인코포레이티드 항-프로게스틴 민감성 종양을 확인하고 치료하기 위한 방법 및 시스템
RU2659173C2 (ru) * 2012-01-13 2018-06-28 Дженентек, Инк. Биологические маркеры для идентификации пациентов для лечения антагонистами vegf

Also Published As

Publication number Publication date
TWI568439B (zh) 2017-02-01
AR100169A1 (es) 2016-09-14
ES2691213T3 (es) 2018-11-26
WO2015162532A1 (en) 2015-10-29
TR201815682T4 (tr) 2018-11-21
TW201545747A (zh) 2015-12-16
MX2016013910A (es) 2017-01-11
SI3134119T1 (sl) 2018-11-30
BR112016024143A2 (pt) 2017-08-15
SG11201607918TA (en) 2016-11-29
JP2015210268A (ja) 2015-11-24
CA2946362C (en) 2019-03-12
EP3134119A1 (en) 2017-03-01
AU2018203086A1 (en) 2018-05-24
US20190331687A1 (en) 2019-10-31
EP3134119B1 (en) 2018-08-22
KR101943177B1 (ko) 2019-01-28
AU2015249513A1 (en) 2016-10-06
RU2651469C1 (ru) 2018-04-19
HUE040167T2 (hu) 2019-02-28
IL247859B (en) 2020-07-30
IL247859A0 (en) 2016-11-30
PL3134119T3 (pl) 2018-12-31
CN106233143B (zh) 2020-01-21
CA2946362A1 (en) 2015-10-29
US20170184602A1 (en) 2017-06-29
KR20160134817A (ko) 2016-11-23
CY1120731T1 (el) 2019-12-11
JP6603474B2 (ja) 2019-11-06
CN106233143A (zh) 2016-12-14
DK3134119T3 (en) 2018-10-22
PT3134119T (pt) 2018-11-07
AU2020200237A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
ZA201702382B (en) Combination therapy for cancer
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
SI3231444T1 (sl) Novo zdravljenje
HK1231381A1 (zh) 癌症組合療法
HK1231561A1 (zh) 癌症治療
IL246761A0 (en) Combined cancer treatment
GB201409363D0 (en) Skin cancer treatment
GB201408297D0 (en) Treatment of cancer
HK1251794A1 (zh) 癌症治療
GB201522433D0 (en) Cancer treatment
GB201508480D0 (en) Cancer
GB201411027D0 (en) Treatment
GB201417456D0 (en) Treatment of cancer
GB201412411D0 (en) Treatment
GB201411884D0 (en) Cancer therapy
GB201413317D0 (en) Atheroscierosis treatment
GB201412410D0 (en) Treatment
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
GB201400239D0 (en) Treatment
GB201400241D0 (en) Treatment
GB201400240D0 (en) Treatment
GB201400238D0 (en) Treatment
GB201400235D0 (en) Treatment